Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2021 Financial Results

On July 19, 2021 Neurocrine Biosciences, Inc. (Nasdaq: NBIX) reported that it will report second quarter 2021 financial results after the Nasdaq market closes on Tuesday, August 3, 2021 (Press release, Neurocrine Biosciences, JUL 19, 2021, View Source [SID1234584943]). Neurocrine will then host a conference call and webcast to discuss its financial results and provide a company update that day at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Participants can access the live conference call by dialing 866-952-8559 (US) or 785-424-1743 (International) using the conference ID: NBIX. The webcast can also be accessed on Neurocrine’s website under Investors at www.neurocrine.com. A replay of the webcast will be available on the website approximately one hour after the conclusion of the event and will be archived for approximately one month.

OncXerna Therapeutics to Present at The LifeSci Partners Private Company Summer Symposium

On July 19, 2021 OncXerna Therapeutics, Inc. ("OncXerna"), a precision medicine company using an innovative RNA-expression based biomarker platform to predict patient responses to its first-in-class targeted oncology therapies, reported that Laura Benjamin, Ph.D., Founder and CEO of OncXerna, will present at the LifeSci Partners Private Company Summer Symposium taking place virtually from July 21-23, 2021 (Press release, OncXerna Therapeutics, JUL 19, 2021, View Source [SID1234584944]). Please click the following link to register for the event: Register Here

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Iovance Biotherapeutics to Host Second Quarter Financial Results Conference Call and Webcast on Thursday, August 5, 2021

On July 19, 2021 Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, reported that it will report its second quarter financial results on Thursday, August 5, 2021 (Press release, Iovance Biotherapeutics, JUL 19, 2021, View Source [SID1234584962]). Management will host a conference call and live audio webcast to discuss these results and provide a corporate update at 4:30 p.m. ET.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

To participate in the conference call, please dial 1-844-646-4465 (domestic) or 1-615-247-0257 (international) and reference the access code 1489438. The live webcast can be accessed in the Investors section of the Company’s website at www.iovance.com. The archived webcast will also be available for one year in the Investors section at www.iovance.com.

Scandion Oncology announces that its President & CEO has bought 4,500 shares in Scandion Oncology

On July 19, 2021 Scandion Oncology A/S ("Scandion Oncology") reported that its President & CEO, Bo Rode Hansen, has bought additional 4,500 shares in Scandion Oncology resulting in a total holding on 40,400 shares in the Company (Press release, Scandion Oncology, JUL 19, 2021, View Source;ceo-has-bought-4-500-shares-in-scandion-oncology,c3387000 [SID1234584945]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Upstate Cancer Center receives grant from American Cancer Society to support patient transportation needs

On July 19, 2021 SUNY Upstate reported that Cancer patients undergoing treatment frequently require assistance getting to and from facilities, often creating a financial and logistical burden (Press release, SUNY Upstate, JUL 19, 2021, View Source [SID1234584963]). That’s why the American Cancer Society has awarded a $10,000 transportation grant to the Upstate Cancer Center. These funds will be used to address the transportation needs of cancer patients in Central New York.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

To help patients get the critical care they need, American Cancer Society community transportation grants are awarded at a local level to health systems, treatment centers and community organizations. These grants are available in select communities through an application process and focus on addressing unmet transportation needs of cancer patients, particularly vulnerable populations experiencing an unequal burden of cancer.

"Disparities predominantly arise from inequities in work, wealth, income, education, housing and overall standard of living, as well as social barriers to high-quality cancer prevention, early detection and treatment services," said Joanie Richter of the American Cancer Society. "The Society collaborates with community health partners to reach individuals in areas with higher burdens of cancer and limited or no access to transportation because even the best treatment can’t work if a patient can’t get there."

The Upstate Cancer Center received a $10,000 transportation grant.

"The goal of this project is to remove transportation as a barrier to receiving cancer treatment," said Richard Kilburg, associate administrator of the Upstate Cancer Center. "We hope to ensure that no Upstate Cancer Center patient misses an appointment due to lack of transportation or lack of transportation resources."

"On behalf of our patients, we thank the American Cancer Society for their generous support," Kilburg said.

Caption: From left: Amy Williams, social worker; Joni Richter, American Cancer Society manager, Strategic Partnerships, Cancer Control Northeast Region; Dick Kilburg, associate administrator of the Upstate Cancer Center; and Linda Naples, financial counselor.